Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 10:27:27 2024-07-04 EDT			5-day change	1st Jan Change
243.2 ^CHF	-1.12%		-2.80%	-0.45%

01:49pm	ROCHE HOLDINGS AG : Gets a Sell rating from Goldman Sachs	ZD
01:14pm	Market Update-European stock markets rise in absence of Wall Street	RE

ROCHE HOLDINGS AG : Jefferies reiterates its Neutral rating

July 02, 2024 at 07:39 am

Jefferies analyst Peter Welford maintains his Neutral opinion on the stock. The target price has been raised to CHF 250 from CHF 240.

Latest news about Roche Holding AG

ROCHE HOLDINGS AG : Gets a Sell rating from Goldman Sachs	07:49am	ZD
Market Update-European stock markets rise in absence of Wall Street	07:14am	RE
ROCHE HOLDINGS AG : UBS sticks Neutral	06:55am	ZD
Dax starts trading firmer - US interest rate policy in focus	06:53am	RE
ROCHE HOLDINGS AG : Sell rating from JP Morgan	03:38am	ZD
European shares advance on rate optimism; UK elections in focus	03:01am	RE
Roche: study in lung cancer fails and is discontinued	02:59am	CF
Roche to halt trial in latest setback for new cancer drug	02:11am	RE
Roche to Halt Lung Cancer Trial After Results Miss Goals	01:36am	DJ
Roche to Halt Trial of Combination Formulation for Non-small Cell Lung Cancer Treatment	01:32am	MT
ROCHE HOLDINGS AG : Berenberg sticks Neutral	07-03	ZD
Goldman Sachs Lowers Price Target on Roche, Maintains Sell Recommendation	07-02	MT
ROCHE HOLDINGS AG : Jefferies reiterates its Neutral rating	07-02	ZD
ROCHE HOLDINGS AG : Goldman Sachs reiterates its Sell rating	07-02	ZD
'HB': Sanofi plans to invest billions in Frankfurt	07-01	DP
ROCHE HOLDINGS AG : Deutsche Bank remains Neutral	07-01	ZD
BioPharma Credit to Provide Additional Funding to LumiraDx Amid Roche Deal	07-01	MT
Swiss Market Index Closes Little Changed Amid Key European Inflation Data	06-28	MT
Roche's Eye Therapy Vabysmo Gets EU Panel's Nod for Additional Indication	06-28	MT
Roche: positive CHMP opinion for Vabysmo in OVR	06-28	CF
Roche: positive CHMP opinion for PiaSky in HPN	06-28	CF
Roche Gets EU Panel's Backing for Rare Blood Disorder Therapy	06-28	MT
Roche's Vabysmo Wins EMA Panel's Backing for Retinal Vein Occlusion Indication	06-28	MT
Roche's Vabysmo Gets CHMP Recommendation for Third Indication Retinal Vein Occlusion	06-28	CI
Roche's Rare Blood Disorder Drug PiaSky Backed for Approval in EU	06-28	MT

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

2024-07-23 - American Society of Retina Specialists Meeting

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 11:50 am

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

246 CHF

Average target price

276.4 CHF

Spread / Average Target

+12.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	-0.45%	221B
ELI LILLY AND COMPANY	+54.07%	809B
NOVO NORDISK A/S	+39.09%	621B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	319B
ABBVIE INC.	+5.72%	289B
ASTRAZENECA PLC	+14.42%	238B
NOVARTIS AG	+14.50%	218B
AMGEN INC.	+7.42%	166B
PFIZER, INC.	-3.79%	157B

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : Jefferies reiterates its Neutral rating

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals